AR123244A1 - Vacuna de salmonella para el tratamiento de coronavirus - Google Patents
Vacuna de salmonella para el tratamiento de coronavirusInfo
- Publication number
- AR123244A1 AR123244A1 ARP210102281A ARP210102281A AR123244A1 AR 123244 A1 AR123244 A1 AR 123244A1 AR P210102281 A ARP210102281 A AR P210102281A AR P210102281 A ARP210102281 A AR P210102281A AR 123244 A1 AR123244 A1 AR 123244A1
- Authority
- AR
- Argentina
- Prior art keywords
- bacterium
- fusion protein
- coronavirus
- treatment
- salmonella
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/215—Coronaviridae, e.g. avian infectious bronchitis virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/22—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Neisseriaceae (F)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/28—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Vibrionaceae (F)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/55—IL-2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
- A61K2039/522—Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
- A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- A61K2039/541—Mucosal route
- A61K2039/542—Mucosal route oral/gastrointestinal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- A61K2039/541—Mucosal route
- A61K2039/543—Mucosal route intranasal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55516—Proteins; Peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/55—Fusion polypeptide containing a fusion with a toxin, e.g. diphteria toxin
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/20011—Coronaviridae
- C12N2770/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/20011—Coronaviridae
- C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Virology (AREA)
- Immunology (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Communicable Diseases (AREA)
- General Chemical & Material Sciences (AREA)
- Pulmonology (AREA)
- Cell Biology (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
La presente invención proporciona una bacteria viva atenuada del género Salmonella que comprende un plásmido recombinante que codifica una proteína de fusión, en la que la proteína de fusión comprende un antígeno de coronavirus y un péptido adyuvante. Reivindicación 1: Una bacteria viva atenuada del género Salmonella que comprende un plásmido recombinante que codifica una proteína de fusión, en donde la proteína de fusión comprende: (i) un antígeno de coronavirus; y (ii) un péptido adyuvante. Reivindicación 2: La bacteria de acuerdo con la reivindicación 1, en donde la bacteria es de la especie Salmonella enterica. Reivindicación 28: Un producto de combinación que comprende: a) la bacteria de acuerdo con una cualquiera de las reivindicaciones 1 a 27; y b) al menos una de las una o más proteínas de fusión codificadas por el plásmido de dicha bacteria. Reivindicación 29: Una vacuna que comprende la bacteria de acuerdo con una cualquiera de las reivindicaciones 1 a 27 o el producto de combinación de acuerdo con la reivindicación 28.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP20191142 | 2020-08-14 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR123244A1 true AR123244A1 (es) | 2022-11-09 |
Family
ID=72087970
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP210102281A AR123244A1 (es) | 2020-08-14 | 2021-08-13 | Vacuna de salmonella para el tratamiento de coronavirus |
Country Status (6)
Country | Link |
---|---|
US (1) | US20220047697A1 (es) |
EP (1) | EP4196158A1 (es) |
AR (1) | AR123244A1 (es) |
TW (1) | TW202208612A (es) |
UY (1) | UY39378A (es) |
WO (1) | WO2022034221A1 (es) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB202215576D0 (en) * | 2022-10-21 | 2022-12-07 | Prokarium Ltd | Circuit |
CN117070535B (zh) * | 2023-10-17 | 2024-01-26 | 中国医学科学院医学生物学研究所 | 具有体液免疫和细胞免疫功能的新冠病毒突变体广谱疫苗 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL276210B2 (en) * | 2013-11-29 | 2024-01-01 | Inovio Pharmaceuticals Inc | MERS-COV vaccine |
KR20220161444A (ko) * | 2020-03-31 | 2022-12-06 | 엔이씨 온코이뮤니티 에이에스 | 새로운 살모넬라-기반의 코로나바이러스 백신 |
US10973908B1 (en) * | 2020-05-14 | 2021-04-13 | David Gordon Bermudes | Expression of SARS-CoV-2 spike protein receptor binding domain in attenuated salmonella as a vaccine |
CN113198010A (zh) * | 2020-12-24 | 2021-08-03 | 重庆医科大学 | 一种新型冠状病毒口服活疫苗及其制备方法 |
-
2021
- 2021-08-13 UY UY0001039378A patent/UY39378A/es unknown
- 2021-08-13 TW TW110129907A patent/TW202208612A/zh unknown
- 2021-08-13 US US17/402,014 patent/US20220047697A1/en active Pending
- 2021-08-13 AR ARP210102281A patent/AR123244A1/es unknown
- 2021-08-13 WO PCT/EP2021/072624 patent/WO2022034221A1/en unknown
- 2021-08-13 EP EP21769894.3A patent/EP4196158A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
US20220047697A1 (en) | 2022-02-17 |
EP4196158A1 (en) | 2023-06-21 |
TW202208612A (zh) | 2022-03-01 |
UY39378A (es) | 2022-01-31 |
WO2022034221A1 (en) | 2022-02-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR123244A1 (es) | Vacuna de salmonella para el tratamiento de coronavirus | |
MX2023000411A (es) | Vacuna combinada de sars-cov-2 e influenza. | |
MX2022015132A (es) | Vacunas combinadas a base de acidos nucleicos. | |
AR107020A2 (es) | Vacuna de pcsk9 (proteína convertasa subtilisina-kexina tipo 9) | |
ES2682670T3 (es) | Lisinas de bacteriófagos de Streptococcus para la detección y tratamiento de bacterias gram positivas | |
CO2021017664A2 (es) | Péptidos | |
PE20030285A1 (es) | Vacunacion en dosis unica con mycoplasma hyopneumoniae | |
AR109538A1 (es) | Vacuna contra la gripe porcina | |
MX2020010076A (es) | Construcciones de polipeptido de lisina-peptido anti-microbiano (amp), lisinas, polinucleotidos aislados que codifican para estas, y sus usos. | |
PE20230171A1 (es) | Vacunas contra el coronavirus y metodos de uso | |
BR112018075440A2 (pt) | composições e métodos para prevenir e tratar a infecção por zika vírus | |
BR112022005687A2 (pt) | Vacinas contra o hbv e métodos para tratar o hbv | |
PE20211095A1 (es) | Composiciones de escherichia coli y metodos de estas | |
AR020084A1 (es) | Pestivirus atenuados | |
BR112022019207A2 (pt) | Composições de vacina para coronavírus e métodos de uso das mesmas | |
AR124522A1 (es) | COMPOSICIÓN INMUNOGÉNICA VIVA RECOMBINANTE QUE COMPRENDE EL VIRUS DE LA ENFERMEDAD DE NEWCASTLE (NDV) QUE EXPRESA LA SUBUNIDAD S1 Y EL RBD DE LA PROTEÍNA SPIKE DEL SARS-CoV-2 | |
PE20201405A1 (es) | Vacuna viva recombinante para sars-cov-2 basada en salmonella enteritidis recombinante | |
UY37448A (es) | Constructos de vacuna y sus usos contra infecciones causadas por staphylococcus | |
AR101932A1 (es) | Agente con propiedades antivirales para prevenir o tratar peces expuestos a un virus de la familia birnaviridae | |
AR117019A1 (es) | Conjugados de interleuquina 10 y usos de los mismos | |
AR125291A1 (es) | Composiciones de vacuna de staphylococcus aureus | |
AR127807A1 (es) | Vacuna contra el coronavirus | |
AR122647A1 (es) | PÉPTIDOS INMUNODOMINANTES DE SARS-CoV-2 Y SUS USOS | |
PE20240636A1 (es) | Combinaciones farmaceuticas para el tratamiento del cancer | |
AR121389A1 (es) | Composiciones de vacuna para prevenir la enfermedad de coronavirus |